合并症与多发性硬化治疗选择及持续性的关联:一项真实世界多中心研究
该研究纳入意大利20个MS中心2010-2016年新诊断的2076例患者,评估诊断时合并症与治疗选择及持续性的关联。结果显示23.9%患者至少有一种合并症,合并症与首次疾病修正治疗选择无关,但与因不耐受换药风险升高相关(HR 1.42,95%CI 1.07-1.87;p=0.014)。
要点
- 诊断时合并症与首次DMT选择无显著关联。
- 合并症与因不耐受换药风险升高独立相关(HR 1.42)。
- 该关联在不同DMT间存在异质性(交互作用p=0.04)。
核心结论
- 诊断时合并症与首次DMT选择无关,但与因不耐受换药风险升高相关,应纳入首次治疗决策。
研究设计与样本
- 意大利20个MS中心的新诊断患者队列(2010-2016年),共2076例,合并症数据可获取1877/2076例(90.4%)。
主要发现
- 449/1877例(23.9%)诊断时至少有一种合并症。
- 诊断年龄是唯一与合并症存在独立相关的基线因素(OR 1.05,95%CI 1.04-1.06;p<0.001)。
- 合并症与首次DMT选择无显著关联。
- 合并症与因不耐受换药风险升高显著相关(HR 1.42,95%CI 1.07-1.87;p=0.014)。
- 合并症与不耐受换药风险的关联在不同治疗间显著异质(干扰素β、醋酸格拉替雷、那他珠单抗或芬戈莫德;交互作用检验p=0.04)。
临床怎么用
- 首次选择DMT时应考虑诊断时合并症,以降低因不耐受换药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether the presence of concomitant diseases at multiple sclerosis (MS) diagnosis is associated with the choice and the treatment persistence in an Italian MS cohort. METHODS: We included newly diagnosed patients (2010-2016) followed in 20 MS centers and collected demographic and clinical data. We evaluated baseline factors related to the presence of comorbidities and the association between comorbidities and the clinical course of MS and the time to the first treatment switch. RESULTS: The study cohort included 2,076 patients. Data on comorbidities were available for 1,877/2,076 patients (90.4%). A total of 449/1,877 (23.9%) patients had at least 1 comorbidity at MS diagnosis. Age at diagnosis (odds ratio 1.05, 95% confidence interval [CI] 1.04-1.06; p < 0.001) was the only baseline factor independently related to the presence of comorbidities. Comorbidities were not significantly associated with the choice of the first disease-modifying treatment, but were significantly associated with higher risk to switch from the first treatment due to intolerance (hazard ratio 1.42, CI 1.07-1.87; p = 0.014). Association of comorbidities with risk of switching for intolerance was significantly heterogeneous among treatments (interferon β, glatiramer acetate, natalizumab, or fingolimod; interaction test, p = 0.04). CONCLUSIONS: Comorbidities at diagnosis should be taken into account at the first treatment choice because they are associated with lower persistence on treatment.
引用
- Laroni A, Signori A, Maniscalco GT, et al. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. Neurology. 2017. PMID: 29093064. doi:10.1212/WNL.0000000000004686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。